SAR1118 is primarily investigated for its potential therapeutic applications in the treatment of eye-related conditions, particularly dry eye disease. It functions as a small molecule integrin antagonist, targeting specific proteins involved in the inflammatory processes of the eye. By inhibiting these pathways, SAR1118 aims to reduce inflammation and alleviate symptoms such as discomfort, redness, and blurred vision associated with dry eye syndrome. Its development represents a targeted approach to managing chronic ocular surface inflammation, offering a potential alternative to traditional treatments like artificial tears or corticosteroids. Research continues to explore its efficacy, safety, and long-term benefits in clinical settings.